In a recent article, The Independent Nigeria highlighted how the latest International Conference on Family Planning (ICFP) hosted in Pattaya City, Thailand in November 2022 provided a platform for important, country-specific conversations aimed at fostering healthy...
The Demographic Dividend Initiative in The New York Times Carolina Cardona, Ph.D., M.H.S., a key member of the Demographic Dividend Initiative team at the Bill & Melinda Gates Institute for Population and Reproductive Health, was recently featured in an article...
At the 2023 Women Deliver Youth Zone this past July 18, over 40 youth-led organizations unveiled the Global Roadmap for Action (GRA) , a youth-driven initiative which seeks to transform the landscape of adolescent and youth sexual and reproductive health. Young people’s needs and aspirations are at the forefront of this growing, youth-driven coalition.
Demographic Dividend Luminaries Series The Shape of Things to Come: Using Economic Demography to Understand the Future Tuesday, 11 July 202311 am EDTFeaturing Ronald D. Lee, Ph.D. The Bill & Melinda Gates Institute for Population and Reproductive Health,...
Demographic Dividend Luminaries Series The Price Tag of Women’s Work at Home: Research and Policy Implications to Attaining a Demographic Dividend The Bill & Melinda Gates Institute for Population and Reproductive Health, the Demographic Dividend...
At the Nexus of Reproductive Health, Gender Equity, & Climate Change The Bill & Melinda Gates Institute for Population and Reproductive Health was honored to host gender and climate expert Sono Aibe for an insightful webinar on the topic of reproductive...
Jose Oying Rimon II, Director of the Bill & Melinda Gates Institute for Population and Reproductive Health at Johns Hopkins Bloomberg School of Public Health, was recently featured in an article from The Economist discussing fertility trends in Africa. The...
Recent federal court rulings to restrict use of FDA-approved drug mifepristone are inconsistent with evidence on safety and efficacy Recent decisions regarding approval of the FDA-approved drug mifepristone contradicts over 100 peer-reviewed studies. The drug has been...
